Human Genome Sciences Inc, which has rejected a hostile $13-per-share offer from GlaxoSmithKline, has adopted a short-term stockholder rights plan to fend off such unwanted attention.
Rockville-based Human Genome (NASDAQ: HGSI) said in a statement announcing the plan that it had declared a dividend of one share purchase right for each share of the company’s common stock held of record at the close of business on May 29.
{iframe}http://www.bizjournals.com/baltimore/news/2012/05/17/human-genome-sciences-adopts.html?ana=e_du_pub&s=article_du&ed=2012-05-17{/iframe}